secwatch.observer — SEC 8-K summary
======================================

Issuer:     AIM ImmunoTech Inc. (AIM)
CIK:        0000946644
Form:       8-K
Filed at:   2026-05-14T12:45:38+00:00
Accession:  0001493152-26-022891
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AIM ImmunoTech reports Ampligen pancreatic cancer data: OS improvement 7.2 months vs historical controls
--------------------------------------------------------------------------------

- Named Patient Program shows PFS 12.6 months (+4 mo) and OS 19.7 months (+7.2 mo) vs historical controls.
- DURIPANC Phase 2 with AstraZeneca's Imfinzi interim data suggests improved QoL; mid-2026 report due June.
- Stratified by Neutrophil/Lymphocyte ratio <4.5: PFS 17.7 months (+9.1 mo) and OS 34.8 months (+22.3 mo).
- CA 19-9 <1000 subgroup: PFS 13.1 months (+4.5 mo) and OS 24.1 months (+11.6 mo).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946644/000149315226022891/0001493152-26-022891-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946644/000149315226022891/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-022891

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer